CTX vs. LABS, HEXO, VIR, ZOM, META, VM, DB, NRTH, MRV, and CWEB
Should you be buying Crescita Therapeutics stock or one of its competitors? The main competitors of Crescita Therapeutics include MediPharm Labs (LABS), HEXO (HEXO), Viridium Pacific Group (VIR), Zomedica Pharmaceuticals Corp. (ZOM.V) (ZOM), Meta Growth (META), Voyageur Pharmaceuticals (VM), Decibel Cannabis (DB), 48North Cannabis (NRTH), Nuvo Pharmaceuticals (MRV), and Charlotte's Web (CWEB). These companies are all part of the "drug manufacturers - specialty & generic" industry.
Crescita Therapeutics vs.
MediPharm Labs (TSE:LABS) and Crescita Therapeutics (TSE:CTX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, dividends, institutional ownership, media sentiment, community ranking, analyst recommendations and earnings.
Crescita Therapeutics received 35 more outperform votes than MediPharm Labs when rated by MarketBeat users. Likewise, 67.42% of users gave Crescita Therapeutics an outperform vote while only 65.79% of users gave MediPharm Labs an outperform vote.
MediPharm Labs has a beta of 0.88, meaning that its share price is 12% less volatile than the S&P 500. Comparatively, Crescita Therapeutics has a beta of 1.69, meaning that its share price is 69% more volatile than the S&P 500.
Crescita Therapeutics has lower revenue, but higher earnings than MediPharm Labs. Crescita Therapeutics is trading at a lower price-to-earnings ratio than MediPharm Labs, indicating that it is currently the more affordable of the two stocks.
0.7% of MediPharm Labs shares are owned by institutional investors. 4.5% of MediPharm Labs shares are owned by insiders. Comparatively, 10.9% of Crescita Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
In the previous week, MediPharm Labs' average media sentiment score of 0.00 equaled Crescita Therapeutics'average media sentiment score.
Crescita Therapeutics has a net margin of -15.73% compared to MediPharm Labs' net margin of -30.56%. Crescita Therapeutics' return on equity of -15.60% beat MediPharm Labs' return on equity.
Summary
Crescita Therapeutics beats MediPharm Labs on 7 of the 13 factors compared between the two stocks.
Get Crescita Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CTX and its competitors with MarketBeat's FREE daily newsletter.
Media Sentiment Over Time
This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Crescita Therapeutics Competitors List
Related Companies and Tools
This page (TSE:CTX) was last updated on 4/12/2025 by MarketBeat.com Staff
